Pfizer and Mylan Back To Court In Lengthy Dispute

Law360, New York (November 5, 2005, 12:00 AM EST) -- In the most recent development in a court battle that is poised to enter its fourth year, a district court judge denied both the Mylan’s and Pfizer’s requests for summary judgment, sending the drug companies back to court over the patents for $2.5 billion drug Norvasc.

A judge in the U.S. District Court for the Western District of Pennsylvania denied Mylan’s motion for summary judgment seeking the invalidity of one of Pfizer’s patents for the hypertension drug.

The judge also refused to grant Pfizer’s motion for...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.